TW202321211A - 菸鹼醯胺ripk1抑制劑 - Google Patents

菸鹼醯胺ripk1抑制劑 Download PDF

Info

Publication number
TW202321211A
TW202321211A TW111129732A TW111129732A TW202321211A TW 202321211 A TW202321211 A TW 202321211A TW 111129732 A TW111129732 A TW 111129732A TW 111129732 A TW111129732 A TW 111129732A TW 202321211 A TW202321211 A TW 202321211A
Authority
TW
Taiwan
Prior art keywords
mmol
hydrogen
unsubstituted
methyl
substituted
Prior art date
Application number
TW111129732A
Other languages
English (en)
Chinese (zh)
Inventor
凱文 派翠克 庫薩克
麥可 傑樂 霍門
大衛 安卓 金斯曼
山米 歐斯曼
詹姆士 派翠克 史丹布利
瑪麗亞 安娜史塔西亞 雅吉莉亞迪
席雅瑞 歐萊利
漢娜 德克斯特
尤恩 弗黛希
高雷 史提夫 聖
Original Assignee
美商艾伯維有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾伯維有限公司 filed Critical 美商艾伯維有限公司
Publication of TW202321211A publication Critical patent/TW202321211A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
TW111129732A 2021-08-10 2022-08-08 菸鹼醯胺ripk1抑制劑 TW202321211A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163231590P 2021-08-10 2021-08-10
US63/231,590 2021-08-10

Publications (1)

Publication Number Publication Date
TW202321211A true TW202321211A (zh) 2023-06-01

Family

ID=83439074

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111129732A TW202321211A (zh) 2021-08-10 2022-08-08 菸鹼醯胺ripk1抑制劑

Country Status (15)

Country Link
US (2) US11767310B2 (cg-RX-API-DMAC10.html)
EP (2) EP4643949A3 (cg-RX-API-DMAC10.html)
JP (2) JP7406672B2 (cg-RX-API-DMAC10.html)
KR (2) KR102707109B1 (cg-RX-API-DMAC10.html)
CN (1) CN117460722A (cg-RX-API-DMAC10.html)
AR (1) AR126733A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022328136A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023025850A2 (cg-RX-API-DMAC10.html)
CA (1) CA3219155A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023017151A2 (cg-RX-API-DMAC10.html)
IL (1) IL308349A (cg-RX-API-DMAC10.html)
MX (1) MX2023014817A (cg-RX-API-DMAC10.html)
TW (1) TW202321211A (cg-RX-API-DMAC10.html)
WO (1) WO2023018643A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202310682B (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202321211A (zh) 2021-08-10 2023-06-01 美商艾伯維有限公司 菸鹼醯胺ripk1抑制劑

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005131A1 (en) 1995-08-02 1997-02-13 J. Uriach & Cia. S.A. New carboxamides with antifungal activity
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
US6723727B1 (en) 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
CA2533889A1 (en) 2003-08-15 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
US7465746B2 (en) 2003-08-15 2008-12-16 Merck & Co., Inc. Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP
US7112316B1 (en) 2005-08-08 2006-09-26 Uop Llc Process for preparing molecular sieves via continuous addition of nutrients
EP1984355A2 (en) 2006-02-16 2008-10-29 Takeda Pharmaceutical Company Limited Cyclic amine compound and use thereof for the prophylaxis or treatment of hypertension
ATE505454T1 (de) 2007-09-20 2011-04-15 Amgen Inc 1-(4-(4-benzylbenzamid)-benzyl)-azetidin-3- carboxylsäurederivate und entsprechende verbindungen als s1p-rezeptor-modulatoren zur behandlung von immunerkrankungen
AU2009225869B2 (en) 2008-03-18 2014-01-23 Merck Sharp & Dohme Llc Substituted 4-hydroxypyrimidine-5-carboxamides
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
WO2011113707A1 (en) 2010-03-17 2011-09-22 Exxonmobil Chemical Patents Inc. Plasticiser blends and compositions and articles made therefrom
CA2815131C (en) 2010-10-20 2020-06-09 Gruenenthal Gmbh Substituted 6-amino-nicotinamides as kcnq2/3 modulators
WO2013049255A1 (en) 2011-09-26 2013-04-04 Vanderbilt University Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors
TWI648274B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 （二）
EA032355B1 (ru) 2013-12-24 2019-05-31 Онкотартис, Инк. Бензамидные и никотинамидные соединения и способы их применения
KR101555033B1 (ko) 2014-07-28 2015-09-23 충남대학교산학협력단 신규한 메타논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
KR101551313B1 (ko) 2014-07-28 2015-09-09 충남대학교산학협력단 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
RU2017109122A (ru) 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
EP3224237B1 (en) 2014-12-24 2024-09-11 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
RU2716136C2 (ru) 2015-07-02 2020-03-06 Ф. Хоффманн-Ля Рош Аг Бициклические лактамы и способы их применения
WO2017069279A1 (ja) 2015-10-23 2017-04-27 武田薬品工業株式会社 複素環化合物
CN108602809B (zh) 2015-12-04 2022-09-30 戴纳立制药公司 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
EP3515447A4 (en) 2016-09-26 2020-05-27 Tufts University Uridine nucleoside derivatives, compositions and methods of use
LT3580220T (lt) 2017-02-13 2021-12-27 Bristol-Myers Squibb Company Aminotriazolopiridinai, kaip kinazės inhibitoriai
DE102017211104B3 (de) 2017-06-29 2018-10-18 Bundesdruckerei Gmbh Verfahren und Vorrichtung zum Verifizieren eines elektrolumineszierenden Sicherheitsmerkmals in einem Wert- oder Sicherheitsdokument unter Ausnutzung von zusätzlicher Lichtstrahlung
CN111566103B (zh) * 2017-10-30 2023-06-23 百时美施贵宝公司 作为激酶抑制剂的氨基咪唑并吡嗪
US11618753B2 (en) * 2018-01-26 2023-04-04 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
SI3788044T1 (sl) 2018-05-03 2023-12-29 Rigel Pharmaceuticals, Inc. Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo
WO2020007234A1 (zh) * 2018-07-02 2020-01-09 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基(杂)芳环类化合物
WO2020013531A1 (ko) 2018-07-10 2020-01-16 보로노이바이오 주식회사 N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
WO2020149553A1 (ko) * 2019-01-15 2020-07-23 주식회사 보로노이 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
TW202321211A (zh) 2021-08-10 2023-06-01 美商艾伯維有限公司 菸鹼醯胺ripk1抑制劑

Also Published As

Publication number Publication date
MX2023014817A (es) 2024-01-12
ZA202310682B (en) 2024-08-28
CN117460722A (zh) 2024-01-26
EP4301744A1 (en) 2024-01-10
EP4643949A2 (en) 2025-11-05
AR126733A1 (es) 2023-11-08
AU2022328136A1 (en) 2023-11-30
JP2024037892A (ja) 2024-03-19
KR20230163568A (ko) 2023-11-30
JP2023549007A (ja) 2023-11-22
US20230127127A1 (en) 2023-04-27
IL308349A (en) 2024-01-01
CA3219155A1 (en) 2023-02-16
KR20240135076A (ko) 2024-09-10
EP4643949A3 (en) 2026-01-07
US11767310B2 (en) 2023-09-26
US20240360099A1 (en) 2024-10-31
WO2023018643A1 (en) 2023-02-16
JP7406672B2 (ja) 2023-12-27
BR112023025850A2 (pt) 2024-03-05
CO2023017151A2 (es) 2023-12-29
KR102707109B1 (ko) 2024-09-20

Similar Documents

Publication Publication Date Title
KR102092812B1 (ko) 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
KR102297587B1 (ko) 치환된 n-헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
EP3347018B1 (en) Inhibitors of cyclin-dependent kinases
KR101931435B1 (ko) 신규한 이미다조피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
JP5752232B2 (ja) プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
TWI764052B (zh) 含硼之pde4抑制劑
WO2016160617A2 (en) Inhibitors of cyclin-dependent kinases
RU2730849C1 (ru) Производное пирроло-пиридинового соединения, способ его получения и фармацевтическая композиция, содержащая его в качестве активного ингредиента, для профилактики и лечения заболеваний, связанных с протеинкиназой
AU2016283100A1 (en) Fused bicyclic pyrimidine derivatives and uses thereof
EP3209648B1 (en) Thiazolyl-containing compounds for treating proliferative diseases
KR20200051832A (ko) 벤조티아졸 화합물 및 신경퇴행성 질환을 치료하기 위한 그의 사용 방법
KR20190108080A (ko) 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물
KR20200020622A (ko) 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
US20240360099A1 (en) Nicotinamide ripk1 inhibitors
KR20200029946A (ko) 신규 피리도-피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
WO2024151809A1 (en) Inhibitors of bone morphogenetic protein receptor type 2 (bmpr2) and methods using same
US11339161B2 (en) Triazolo pyridines as modulators of gamma-secretase
RU2778370C2 (ru) Бензотиазольные соединения и способы их применения для лечения нейродегенеративных расстройств
WO2026064579A2 (en) Small molecule protein synthesis modulators
CA2972239A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2988330A1 (en) 4,6-pyrimidinylene derivatives and uses thereof